Understanding the role of mutations and biomarker testing is one of most important things patients must learn. Uncovering the driving force behind each individual’s tumors is not just important, it is critical. Here is a Resource list for GIST and other cancers.
Understanding the role of mutations and biomarker testing is one of most important things patients must learn. Uncovering the driving force behind each individual’s tumors is not just important, it is critical. This video talks about why it's important.
It is time to stop talking and take action to assure patients get tested. The goal of the 'It's Time' campaign is to increase and improve the understanding of biomarker testing in the cancer community and get patients tested.
Understanding the role of mutations and biomarker testing is one of most important things patients must learn. Uncovering the driving force behind each individual’s tumors is not just important, it is [...]
Dr. Gina D'Amato, who appeared recently as moderator and contributor for the first Women in Sarcoma discussion panel, recorded a video discussing the use of liquid biopsy in sarcoma on OncTV for OncLive.
In a recent post by Oncology Nursing News, Dr. Gina D'Amato, associate professor and assistant director of Clinical Research at Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses the evolution of treatment in sarcoma, the use of NGS, and predictive and prognostic biomarkers under investigation in the space.
Blueprint Medicines presented a poster titled “The Cost Impact of Increased Molecular Testing Rates for the Treatment of Patients with Gastrointestinal Stromal Tumors” at the annual meeting of the AMCP.
The LRG, in collaboration with the Pediatric & SDH-Deficient GIST Consortium and key opinion leaders among the GIST pathology community (with Dr. Brian Rubin taking the lead), played a significant role in changing CAP Guidelines. CAP Guidelines are protocols for pathologists to instruct them on the process of diagnosing a disease based on tumor tissue samples.
Genetic Testing and SDHx Mutations: What do they have to do with PGL/GIST/Pheos? This webcast highlights how SDHx mutations impact risks for paraganglioma, pheochromocytomas, and GIST, why genetic testing is helpful for any diagnosis [...]
GI Stromal Tumors: A PatholoGIST's Point of View Mutational Testing in GIST Mutational Testing in GIST is a vital component for survival, especially as cancer treatment becomes more individualized. In this webcast, Dr. Chris [...]
